Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Guo, Ting ^a   Woo, Shih Lung ^a   Guo, Xin ^a   Li, Honggui ^a   Zheng, Juan ^a,b   Botchlett, Rachel ^a   Liu, Mengyang ^a   Pei, Ya ^a   Xu, Hang ^a   Cai, Yuli ^a,b   Zeng, Tianshu ^b   Chen, Lulu ^b   Li, Xiaodong ^c   Li, Qifu ^d   Xiao, Xiaoqiu ^d   Huo, Yuqing ^e,f   Wu, Chaodong ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

^d THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

^f PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; BERBERINE; FATTY ACID SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; STRESS ACTIVATED PROTEIN KINASE 1;

ADIPOSE TISSUE; ANIMAL; BIOSYNTHESIS; CHEMICALLY INDUCED; DRUG EFFECTS; FAT INTAKE; GENE EXPRESSION REGULATION; METABOLISM; MOUSE; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOLOGY; PHARMACOLOGY;

ACETYL-COA CARBOXYLASE; ADIPOSE TISSUE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BERBERINE; DIETARY FATS; FATTY ACID SYNTHASE, TYPE I; GENE EXPRESSION REGULATION, ENZYMOLOGIC; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 8; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY;

EID: 84960153111     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22612     Document Type: Article

References (47)

1. Marchesini, G. et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37, 917-923 (2003).
2. Marrero, J. A. et al. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36, 1349-1354 (2002).
3. Starley, B. Q., Calcagno, C. J. & Harrison, S. A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51, 1820-1832 (2010).
4. Tilg, H. & Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52, 1836-1846 (2010).
5. Farrell, G. C. & Larter, C. Z. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 43, S99-S112 (2006).
6. van der Poorten, D. et al. Visceral fat: A key mediator of steatohepatitis in metabolic liver disease. Hepatology 48, 449-457 (2008).
7. Joshi-Barve, S. et al. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 46, 823-830 (2007).
8. Nakamura, S. et al. Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. J. Biol. Chem. 284, 14809-14818 (2009).
9. Samuel, V. T. et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 279, 32345-32353 (2004).
10. Targher, G. et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54, 3541-3546 (2005).
11. Kang, K. et al. Adipocyte-derived Th2 cytokines and myeloid PPARd regulate macrophage polarization and insulin sensitivity. Cell Metab 7, 485-495 (2008).
12. Odegaard, J. I. et al. Alternative M2 activation of Kupffer cells by PPARd ameliorates obesity-induced insulin resistance. Cell Metab 7, 496-507 (2008).
13. Menghini, R. et al. Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 136, 663-672. e664 (2009).
14. Park, E. J. et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140, 197-208, doi: 10.1016/j.cell.2009.12.052 (2010).
15. Huo, Y. et al. Targeted overexpression of inducible 6-phosphofructo-2-kinase in adipose tissue increases fat deposition but protects against diet-induced insulin resistance and inflammatory responses. J. Biol. Chem. 287, 21492-21500 (2012).
16. Guo, X. et al. Palmitoleate induces hepatic steatosis but suppresses liver inflammatory response in mice. PLoS ONE 7, e39286 (2012).
17. Lee, Y. S. et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55, 2256-2264, doi: 10.2337/db06-0006 (2006).
18. Yin, J., Gao, Z., Liu, D., Liu, Z. & Ye, J. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab 294, E148-E156 (2008).
19. Chang, X. et al. Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J Lipid Res 51, 2504-2515, doi: 10.1194/jlr.M001958 (2010).
20. Yan, H.-M. et al. Efficacy of berberine in patients with non-alcoholic fatty liver disease. PLoS ONE 10, e0134172, doi: 10.1371/ journal.pone.0134172 (2015).
21. Kim, W. S. et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab 296, E812-E819, doi: 10.1152/ajpendo.90710.2008 (2009).
22. Zhang, Y. et al. Berberine reverses abnormal expression of L-type pyruvate kinase by DNA demethylation and histone acetylation in the livers of the non-alcoholic fatty disease rat. Int J Clin Exp Med 8, 7535-7543 (2015).
23. Zang, M. et al. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J. Biol. Chem. 279, 47898-47905 (2004).
24. Lou, T. et al. Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes. Inflammation 34, 659-667, doi: 10.1007/s10753-010-9276-2 (2011).
25. Wu, C. et al. Enhancing hepatic glycolysis reduces obesity: Differential effects on lipogenesis depend on site of glycolytic modulation. Cell Metab 2, 131-140 (2005).
26. Woo, S.-L. et al. Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. PLoS ONE 9, e91111, doi: 10.1371/journal.pone.0091111 (2014).
27. Schaffler, A., Scholmerich, J. & Buchler, C. Mechanisms of Disease: adipocytokines and visceral adipose tissue-emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2, 273-280 (2005).
28. Jeong, H. W. et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab 296, E955-E964, doi: 10.1152/ajpendo.90599.2008 (2009).
29. Cui, G. et al. Berberine differentially modulates the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation in type 1 diabetic mice. J. Biol. Chem. 284, 28420-28429, doi: 10.1074/jbc.M109.012674 (2009).
30. Choi, B.-H. et al. Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. Exp Mol Med 38, 599-605 (2006).
31. Schattenberg, J. M. et al. Jnk1 but not jnk2 promotes the development of steatohepatitis in mice. Hepatology 43, 163-172 (2006).
32. Ma, K. L. et al. Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology 48, 770-781 (2008).
33. Saberi, M. et al. Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab 10, 419-429 (2009).
34. Singh, R. et al. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology 49, 87-96, doi: 10.1002/hep.22578 (2009).
35. Li, L. et al. Nuclear factor high-mobility group box1 mediating the activation of toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology 54, 1620-1630 (2011).
36. Baeck, C. et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61, 416-426 (2012).
37. Brusq, J.-M. et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 47, 1281-1288, doi: 10.1194/jlr.M600020-JLR200 (2006).
38. Assifi, M. M. et al. AMP-activated protein kinase and coordination of hepatic fatty acid metabolism of starved/carbohydrate-refed rats. Am J Physiol Endocrinol Metab 289, E794-800 (2005).
39. Xu, M. et al. Berberine promotes glucose consumption independently of AMP-activated protein kinase activation. PLoS ONE 9, e103702, doi: 10.1371/journal.pone.0103702 (2014).
40. Wu, C., Okar, D. A., Newgard, C. B. & Lange, A. J. Overexpression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in mouse liver lowers blood glucose by suppression of hepatic glucose production. J. Clin. Invest. 107, 91-98 (2001).
41. Wu, C. et al. Perturbation of glucose flux in the liver by decreasing fructose-2,6-bisphosphate levels causes hepatic insulin resistance and hyperglycemia. Am J Physiol Endocrinol Metab 291, E536-543 (2006).
42. Huo, Y. et al. Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity but exacerbates systemic insulin resistance and adipose tissue inflammatory response. J. Biol. Chem. 285, 3713-3721 (2010).
43. Guo, X. et al. Involvement of inducible 6-phosphofructo-2-kinase in the anti-diabetic effect of PPARg activation in mice. J. Biol. Chem. 285, 23711-23720 (2010).
44. Stienstra, R. et al. Peroxisome proliferator-activated receptor g activation promotes infiltration of alternatively activated macrophages into adipose tissue. J. Biol. Chem. 283, 22620-22627 (2008).
45. Prieur, X. et al. Differential lipid partitioning between adipocytes and tissue macrophages modulates macrophage lipotoxicity and M2/M1 polarization in obese mice. Diabetes 60 797-809 (2011).
46. Li, Y. et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metabolism 13, 376-388 (2011).
47. Guo, X. et al. Disruption of inducible 6-phosphofructo-2-kinase impairs the suppressive effect of PPARg activation on diet-induced intestine inflammatory response. J Nutr Biochem 24, 770-775 (2013).